Bristol Myers Drops Orum's Degrader-Antibody Cancer Program

Bristol Myers Squibb disclosed in a Thursday regulatory filing that it has ended development of BMS-986497/ORM-6151, a Phase 1 degrader-antibody conjugate licensed from Orum Therapeutics in a deal referenced at $100 million.

Bristol Myers Squibb (BMY) has walked away from BMS-986497/ORM-6151, an early-stage cancer program it licensed from South Korea's Orum Therapeutics, according to a regulatory filing made on Thursday. The asset was in Phase 1, the earliest stage of human testing, and represented a variation on one of oncology's most crowded and best-funded ideas: the antibody-drug conjugate.

The discontinuation was reported by Endpoints News, which noted the deal behind the molecule carried a $100 million figure. For Orum, a company whose public profile rests substantially on that partnership, the decision removes the most visible clinical validation of its approach from a large-cap partner's pipeline.

What the discontinued molecule was trying to do

Antibody-drug conjugates, or ADCs, work by bolting a potent cell-killing payload onto an antibody that recognises a marker on the surface of a tumour cell. The antibody acts as the postcode; the payload does the damage once inside. The field has absorbed enormous amounts of capital over the past several years, and nearly every large oncology developer now runs multiple ADC programs.

Orum's pitch is a twist on that architecture. Instead of a conventional chemotherapy-style payload, the company attaches a targeted protein degrader — a molecule designed to hijack the cell's own disposal machinery and destroy a specific protein rather than merely block it. The resulting construct is usually described as a degrader-antibody conjugate. The theory is that the antibody delivers a mechanism that is hard to dose safely on its own, confining the degrader's activity to cells that carry the right surface marker.

BMS-986497/ORM-6151 was the test case for that theory inside a major pharmaceutical company. Ending it at Phase 1 does not, by itself, invalidate the platform. Phase 1 trials exist to answer questions about safety, tolerability and dose, and most molecules that enter them never reach registration. But it does mean the concept loses its highest-profile clinical champion for now.

The milestone economics facing Orum

Licensing deals of this shape are almost always structured the same way: a modest payment on signing, then a ladder of milestone payments tied to advancement through preclinical, clinical and regulatory stages, with royalties at the far end. Headline deal values — here referenced at $100 million — describe the top of that ladder, not cash in hand.

When a partner discontinues the asset, the rungs above the current stage stop being reachable. Whatever Orum has already received is retained; whatever was contingent on Phase 2 initiation, pivotal data or approval is not paid. That is the practical consequence for a smaller biotech: the headline number quoted in the original announcement was never the realistic expectation, and now the gap between headline and realised value is fixed rather than open.

Rights to a discontinued asset also typically revert to the originator, though the specific terms were not disclosed in the filing. Whether Orum chooses to reclaim and re-partner the molecule, redirect resources to other degrader-antibody candidates, or treat the program as closed is the decision that matters most to its investors over the next several quarters.

Where this sits in Bristol Myers' pipeline housekeeping

Large pharmaceutical companies prune early pipelines routinely, and disclosure of those cuts through regulatory filings is the normal mechanism. A Phase 1 discontinuation at a company of Bristol Myers' scale is a portfolio management decision, not a corporate event — it does not alter near-term revenue and it does not signal anything about late-stage programs.

What it does signal is a choice about where scarce development capacity goes. Bristol Myers, like its peers, is running more oncology candidates than it can fund through registration. The bar for advancing a first-in-class mechanism past Phase 1 is high precisely because the conventional ADC playbook — validated targets, validated payloads — now has a long track record to compete against. A novel payload class has to clear that comparison, not just clear a safety threshold.

For the broader degrader-antibody field, the read-through is limited but real. Investors evaluating other companies working on conjugated degraders will now be asking what specifically drove the decision, and whether the answer relates to the molecule, the target or the architecture. The filing itself does not answer that.

How the shares closed

Bristol Myers shares last traded at 63.06, up 0.35% on the day, against a previous close of 62.84, with a session range of 62.19 to 63.06. Markets are closed; that is the most recent close, as of 20:00 GMT on Friday, 18 September 2026.

The move is consistent with a stock that absorbed the news as pipeline routine rather than as a setback of consequence. The close came against a mixed broad tape: the S&P 500 tracker (SPY) ended at $761.69, down 0.12%, the Dow 30 tracker (DIA) at $515.88, down 0.48%, while the Nasdaq 100 tracker (QQQ) closed at $721.45, up 0.63%.

What to watch from here

Three things will clarify the story. First, any statement from Orum on whether rights revert and what the company intends to do with the molecule. Second, whether Bristol Myers retains other degrader-antibody or novel-payload conjugates in its disclosed pipeline, which would separate a program-level judgement from a platform-level one. Third, the pace of new licensing activity in conjugated degraders across the sector — the clearest single indicator of whether other large buyers still see the architecture as worth paying for.

Until then, the filing says only what it says: a Phase 1 asset has been discontinued, and a $100 million headline deal will not be paid out in full.

Key facts

• Asset discontinued: BMS-986497/ORM-6151, a Phase 1 degrader-antibody conjugate
• Deal value referenced: $100 million, partnered with Orum Therapeutics
• Disclosure: Thursday regulatory filing by Bristol Myers Squibb
• BMY last close: 63.06, +0.35%, as of 20:00 GMT, 18 Sep 2026

Frequently asked questions

What exactly did Bristol Myers discontinue?

Bristol Myers Squibb ended development of BMS-986497/ORM-6151, a cancer candidate it had licensed from Orum Therapeutics. The molecule was in Phase 1, the first stage of human testing, and was a variation on the antibody-drug conjugate approach. The discontinuation was disclosed in a regulatory filing made on Thursday.

What is a degrader-antibody conjugate?

It is an antibody-drug conjugate in which the payload delivered to the tumour cell is a targeted protein degrader rather than a conventional cell-killing chemical. A degrader recruits the cell's own disposal machinery to destroy a specific protein instead of just blocking it. The antibody confines that activity to cells carrying a chosen surface marker.

Does Orum lose the full $100 million?

No. Headline biotech deal values describe the maximum payable if every milestone is hit, not cash received at signing. Orum keeps what has already been paid. What it loses is access to the milestone payments that were contingent on the program advancing past Phase 1 into later trials, regulatory filing and approval.

Is this a serious problem for Bristol Myers?

Not materially. Phase 1 discontinuations are routine portfolio management at large pharmaceutical companies, which run more early candidates than they can fund to registration. The decision does not affect near-term revenue and carries no read-through to late-stage programs. Bristol Myers shares closed higher on the day, at 63.06.

How did Bristol Myers stock react?

Bristol Myers shares last traded at 63.06, up 0.35% from a previous close of 62.84, with a day range of 62.19 to 63.06, as of 20:00 GMT on 18 September 2026. Markets were closed at that point. The modest gain suggests investors treated the filing as pipeline housekeeping rather than a setback.

What should investors watch next?

Whether rights to the molecule revert to Orum and what Orum does with them; whether Bristol Myers keeps other novel-payload conjugates in its disclosed pipeline, which would separate a program-specific judgement from a platform-level one; and whether other large pharmaceutical buyers continue signing licensing deals in conjugated degraders.

Sources

• Bristol Myers scraps $100M Orum-partnered cancer drug — Endpoints News